Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.59 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LATS1 | O95835 | 1/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339239 | 0.89 | ROCK2 (0.55) | ROCK2ROCK1CDC42BPBADRB2NCF1 | |
| Hydrochloric Acid SCHEMBL16235941 | 0.87 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBADRB2NCF1 | |
| SCHEMBL565865 | 0.84 | ROCK2 (0.55) | ROCK2ROCK1CDC42BPBALDH1A1CDC42BPA | |
| SCHEMBL30751784 | 0.84 | ROCK2 (0.55) | ROCK2ROCK1CDC42BPBALDH1A1CDC42BPA | |
| SCHEMBL19095257 | 0.80 | ROCK2 (0.58) | ROCK2ROCK1CDC42BPBALDH1A1CDC42BPA | |
| SCHEMBL30510121 | 0.78 | GSK3B (0.47) | ROCK2ROCK1CDC42BPBCDC42BPAPARP1 | |
| SCHEMBL1904695 | 0.77 | ADRB2 (0.59) | ADRB2NCF1PLD1ALDH1A1LATS1 | |
| SCHEMBL2490932 | 0.77 | CDC42BPB (0.42) | ROCK2ROCK1CDC42BPBCDC42BPAPARP1 | |
| Hydrochloric Acid SCHEMBL2226310 | 0.76 | ROCK2 (0.38) | ROCK2ROCK1CDC42BPBLATS1CDC42BPA | |
| SCHEMBL1631742 | 0.76 | ADRB1 (0.58) | ADRB2NCF1PLD1LATS1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001885-A2 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007100990-A2 | OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-07 | — | — | WO | claimed |
| EP-2970223-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164756-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2001885-A2 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007100990-A2 | OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | ROCK2 4632/4885ROCK1 4717/4885CDC42BPB 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.